Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
Year: 2017
Type: article
Study design: Observational Study
Abstract: In psoriasis, an IL-17-mediated inflammatory skin disease, skin lesions resolve with therapy, but often recur in the same locations when therapy is discontinued. We propose that residual T cell populations in resolved psoriatic lesions represent the pathogenic T cells of origin in this disease. Utilizing high-throughput screening (HTS) of the T cell receptor (TCR) and immunostaining, we found that clinically resolved psoriatic lesions contained oligoclonal populations of T cells that produced IL-17A in both resolved and active psoriatic lesions. Putative pathogenic clones preferentially utilized particular Vβ and Vα subfamilies. We identified 15 TCRβ and 4 TCRα antigen receptor sequences shared between psoriasis patients and not observed in healthy controls or other inflammatory skin conditions. To address the relative roles of αβ versus γδ T cells in psoriasis, we carried out TCR/δ HTS. These studies demonstrated that the majority of T cells in psoriasis and healthy skin are αβ T cells. γδ T cells made up 1% of T cells in active psoriasis, less than 1% in resolved psoriatic lesions, and less than 2% in healthy skin. All of the 70 most frequent putative pathogenic T cell clones were αβ T cells. In summary, IL-17-producing αβ T cell clones with psoriasis-specific antigen receptors exist in clinically resolved psoriatic skin lesions. These cells likely represent the disease-initiating pathogenic T cells in psoriasis, suggesting that lasting control of this disease will require suppression of these resident T cell populations.
DOI: 10.1172/jci93396
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Funders: American Skin Association, National Psoriasis Foundation, AstraZeneca, Brigham and Women's Hospital, AstraZeneca Foundation, Universiteit van Amsterdam, Universidade de Lisboa, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Awards: CTCL immunobiology: lessons from alemtuzumab, G1796438506, Transforming the diagnosis and care of patients with CTCL using TCR sequencing, Immune Evasion in Human Squamous Cell Carcinomas of the Skin, Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination, Skin Homing T Cells, G6958478060, Vaccination to generate protective tissue resident T cells, Dermatology Training Grant, Human Skin Disease Resource-based Center
OpenAlex ID: W2759346956
